Details of the Drug Combination

General Information of Drug Combination (ID: DCAN38K)

Drug Combination Name
Vinflunine PMID28870136-Compound-43
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs Vinflunine   DMTJAEP PMID28870136-Compound-43   DMWGV8N
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: HCT-15
Zero Interaction Potency (ZIP) Score: 1.54
Bliss Independence Score: 7.59
Loewe Additivity Score: 9.73
LHighest Single Agent (HSA) Score: 3.74

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Vinflunine
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [2]
PMID28870136-Compound-43 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Ecto-5'-nucleotidase (CD73) TTK0O6Y 5NTD_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Childhood T acute lymphoblastic leukemia DCXKN42 CCRF-CEM Investigative [4]
Clear cell renal cell carcinoma DCQGTFD CAKI-1 Investigative [4]
Plasma cell myeloma DC4AJUU RPMI-8226 Investigative [4]
Carcinoma DCNH7OL RXF 393 Investigative [5]
Adenocarcinoma DC1EF4G SW-620 Investigative [1]
High grade ovarian serous adenocarcinoma DCTMRAW OVCAR-8 Investigative [1]
High grade ovarian serous adenocarcinoma DCHLELH NCI\\/ADR-RES Investigative [1]
Malignant melanoma DC0O0ZP LOX IMVI Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.